Table 2. Comparison between serum levels of soluble urokinase-type plasminogen activator receptor and plasma levels of fibrinogen, by GOLD stage, in patients with acute exacerbation of COPD.
Marker | GOLD stage | ANOVA | |||
---|---|---|---|---|---|
I or II | III | IV | |||
Mean ± SD | Mean ± SD | Mean ± SD | F | p | |
suPAR (pg/mL) | |||||
Day 1 | 3,504.34 ± 542.53 | 5,309.23 ± 994.52 | 6,760.0 ± 502.81 | 78.232 | < 0.001 |
Day 14 | 2,558.69 ± 607.38 | 4,084.61 ± 1,201.23 | 5,167.77 ± 1,054.14 | ||
Fibrinogen (mg/dL) | |||||
Day 1 | 443.47 ± 107.98 | 595.38 ± 229.98 | 843.33 ± 125.0 | 21.669 | < 0.001 |
Day 14 | 337.82 ± 101.88 | 473.84 ± 201.31 | 677.77 ± 125.07 |
GOLD: Global Initiative for Chronic Obstructive Lung Disease; and suPAR: soluble urokinase-type plasminogen activator receptor.